We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

How to spend it

4 Nov 2021 By Aimee Donnellan

The drugs giant is buying back stock from its rival for $20 bln. It highlights the group run by Severin Schwan’s rich valuation and makes risky M&A less likely. The cash could be less helpful for Novartis, which is still in the middle of a turnaround and has a patchy deal record.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)